Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15123689 
Li WQ, et al. (2004) Interleukin-7 inactivates the pro-apoptotic protein Bad promoting T cell survival. J Biol Chem 279, 29160-6 15123689
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S112-p - BAD (mouse)
Orthologous residues
BAD (human): S75‑p, BAD (mouse): S112‑p, BAD (rat): S113‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  leukemia, T cell leukemia
 Relevant cell lines - cell types - tissues:  D1 (T lymphocyte), T lymphocyte-thymus
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-7 increase
LY294002 IL-7 no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (process):  apoptosis, altered

S136-p - BAD (mouse)
Orthologous residues
BAD (human): S99‑p, BAD (mouse): S136‑p, BAD (rat): S137‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  leukemia, T cell leukemia
 Relevant cell lines - cell types - tissues:  D1 (T lymphocyte), T lymphocyte-thymus
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (mouse) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-7 increase
LY294002 IL-7 inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (process):  apoptosis, altered

S155-p - BAD (mouse)
Orthologous residues
BAD (human): S118‑p, BAD (mouse): S155‑p, BAD (rat): S156‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  leukemia, T cell leukemia
 Relevant cell lines - cell types - tissues:  D1 (T lymphocyte), T lymphocyte-thymus
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (mouse) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-7 increase
LY294002 IL-7 inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (process):  apoptosis, altered


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.